Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

ANTI-MIGRAINE DRUGS - A US AND EUROPEAN MARKET REPORT   

Research Abstract

This report analyzes the US And European markets for Anti-Migraine Drugs in US$ Million. Annual forecasts are provided for the period 2006 through 2015. A six-year historic Analysis is also provided for these markets. The report profiles 59 companies including many key and niche players such as Abbott Laboratories, Inc., Eisai, Inc., Eli Lilly and Company, Johnson & Johnson, Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Pozen., Roxro Pharma, Inc., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix, Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, Novartis AG, and UCB S.A. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6126
Price : $3950
Companies : 59
Pages : 617
Date : February 2010
Market Data Tables : 190

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  ANTI-MIGRAINE DRUGS (Complete Report) Pages : 617   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability And Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II-A. A US AND EUROPEAN MARKET REPORT54$3000
  1. MIGRAINE: AN OVERVIEW.....II-15 $300  
   What is Migraine?.....II-1
What Causes Migraine?.....II-1
1$75
   Migraine Classification.....II-2
Migraine with Aura.....II-2
Migraine without Aura.....II-2
Aura without Headache.....II-2
Abdominal Migraine.....II-2
1$75
   Facial Migraine.....II-3
Basilar Migraine.....II-3
Familial Hemiplegic Migraine.....II-3
Ophthalmoplegic/Ocular Migraine.....II-3
Retinal Migraine.....II-3
Menstrual Migraine.....II-3
1$75
   Status Migraine.....II-4
Migraine Attack Stages.....II-4
I – The Prodrome Stage.....II-4
II – The Aura Stage.....II-4
III – The Headache Stage.....II-4
1$75
   IV – The Postdrome Stage.....II-5
1$75
  2. ANTI-MIGRAINE TREATMENT.....II-69 $525  
   Historical Perspective.....II-6
Migraine Treatment.....II-6
Abortive Drugs.....II-6
1$75
   Selective Serotonin Receptor (5- HTI) Agonists/ Triptans.....II-7
Triptans Approved for the Treatment of Migraine.....II-7
Ergot Alkaloids.....II-7
1$75
   Ergot Alkaloids for the Treatment of Migraine.....II-8
Antiemetics.....II-8
Antiemetics for the Treatment of Migraine.....II-8
Analgesics.....II-8
1$75
   Analgesics for the Treatment of Migraine.....II-91$75
   Prophylactic Drugs.....II-10
Beta-Blockers.....II-10
Calcium Channel Blockers.....II-10
Anticonvulsants.....II-10
1$75
   Tricyclic Antidepressants.....II-11
Non-steroidal Anti-inflammatory Drugs.....II-11
Selective Serotonin Reuptake Inhibitors.....II-11
Serotonin Antagonists.....II-11
Anti-migraine Drugs: Side Effects.....II-11
1$75
   Abortive Drugs: Side Effects.....II-12
Prophylactic Drugs: Side Effects.....II-12
1$75
   Anti-migraine Drugs: Interactions.....II-13
Abortive Medications: Interactions.....II-13
1$75
   Prophylactic Drugs: Interactions.....II-14
1$75
  3. RESEARCH & DEVELOPMENT.....II-154 $200  
   Pipeline Drug Research.....II-15
Pipeline Drug Candidates in Phase III Clinical Trials.....II-15
Pipeline Drug Candidates in Phase II Clinical Trials.....II-15
Clinical Research / Drug Development Initiatives.....II-15
MAP Pharma Announces Positive Phase III Results for Levadex.....II-15
1$75
   Addex Initiates Phase IIb Trials for ADX 10059.....II-16
Asterand and BTG Announce Plans to Commence Phase IIa Trials.....II-16
Alexza Commences Phase IIb Trials of AZ-104.....II-16
Neuralieve Announces Trial Completion of New Migraine Treatment Device.....II-16
1$75
   NeurAxon Announces Encouraging Results of Phase 2 Trials.....II-17
Roxro Pharma Announces ROX-828 Results.....II-17
Merck Announces Encouraging Results of Phase III Study of Telcagepant.....II-17
1$75
   ProEthic Pharmaceuticals Reports Encouraging Phase III Results.....II-18
Recent Migraine Research.....II-18
Study Reveals Cocoa Consumption to Ease Migraine.....II-18
Study Reveals Women with Migraine to be At Lesser Risk of Breast Cancer.....II-18
Study Shows Risk of Migraine to be Less Among High Blood Pressure Patients.....II-18
1$75
  II-B. REGIONAL MARKET PERSPECTIVE.....II-1936 $2850  
   1. THE UNITED STATES.....II-19
A. Market Analysis.....II-19
Current & Future Analysis.....II-19
Historic Analysis.....II-19
Migraine – Prevalence and Economic Burden.....II-19
Anti-Migraine Drugs Market At A Glance.....II-19
1$75
   Triptans – Leading the Anti-Migraine Treatment Race.....II-20
Generic Imitrex Make Foray.....II-20
1$75
   Botox – An Emerging Option for Migraine Prophylaxis.....II-21
Anti-migraine Drugs – Limitations Abound.....II-21
The Quest to Unravel the Mystery of Cause of Migraine Continues .....II-21
1$75
   Strategic Corporate Developments.....II-22
Zogenix, Astellas Pharma Sign Agreement for Sumavel DosePro.....II-22
Kowa Pharma to Divest Diclofenac Franchise.....II-22
Zogenix Wins FDA Approval for Sumavel DosePro.....II-22
1$75
   Orchid Pharma Obtains FDA Approval for Sumatriptan Succinate Tablets.....II-23
Sandoz Unveils Sumatriptan and Calcitonin- Salmon Nasal Spray.....II-23
Wockhardt to Introduce Divalproex ER.....II-23
Ranbaxy Receives FDA Approval for Imitrex Generic.....II-23
1$75
   Kowa America Secures FDA Approval for Cambia.....II-24
Almirall Receives FDA Approval for Axert/ Almogran.....II-24
Wockhardt Receives FDA Approval for Sumatriptan Injections.....II-24
Teva Pharmaceutical Secures Approval, Launches Imitrex Generic.....II-24
AstraZeneca Unveils Zomig Rapimeltt in 5 mg Dosage Strength.....II-24
1$75
   Bedford Laboratories Launches Sumatriptan Succinate Injection.....II-25
Ipca Laboratories and Heritage Pharmaceuticals Announce Strategic Alliance.....II-25
Dr. Reddy's Introduces Approved Imitrex® Generic.....II-25
US FDA Approves Divalproex Sodium Tablets.....II-25
1$75
   GSK and Pozen Announce FDA Approval for Treximet.....II-26
Aurobindo Wins Provisionary Approval for Sumatriptan Succinate Tablets.....II-26
Par Pharmaceuticals to Commence Shipment of Imitrex’s Generic Version.....II-26
Select Players.....II-26
Abbott Laboratories, Inc......II-26
1$75
   Eisai, Inc......II-271$75
   Eli Lilly and Company.....II-28
Johnson & Johnson, Inc......II-28
1$75
   Kowa Pharmaceuticals America, Inc......II-29
MAP Pharmaceuticals, Inc......II-29
Merck & Co., Inc......II-29
1$75
   Pfizer, Inc......II-30
Pozen.....II-30
1$75
   Roxro Pharma, Inc......II-31
Winston Pharmaceuticals, Inc......II-31
Wyeth Consumer Healthcare.....II-31
1$75
   Zogenix, Inc......II-32
B. Market Analytics.....II-32
Table 1: US Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-32
1$150
   Table 2: US Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-331$150
   2. EUROPE.....II-34
A. Market Analysis.....II-34
Current & Future Analysis.....II-34
Historic Analysis.....II-34
Strategic Corporate Developments.....II-34
Orexo Acquires PharmaKodex.....II-34
1$75
   Noxxon Pharma Collaborates with Eli Lilly.....II-35
Select Players.....II-35
AstraZeneca Plc (UK).....II-35
Bayer AG (Germany).....II-35
1$75
   Ethypharm S.A. (France).....II-36
GlaxoSmithKline Plc (UK).....II-36
1$75
   Meda AB (Sweden).....II-37
Novartis AG (Switzerland).....II-37
UCB S.A. (Belgium).....II-37
1$75
   B. Market Analytics.....II-38
Table 3: European Recent Past, Current & Future Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-38
1$150
   Table 4: European Historic Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figure in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-391$150
   Table 5: European 15-year Perspective for Anti-Migraine Drugs by Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-401$150
   2a. FRANCE.....II-41
A. Market Analysis.....II-41
Current & Future Analysis.....II-41
Historic Analysis.....II-41
B. Market Analytics.....II-41
Table 6: French Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-41
1$150
   Table 7: French Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-421$150
   2b. GERMANY.....II-43
A. Market Analysis.....II-43
Current & Future Analysis.....II-43
Historic Analysis.....II-43
B. Market Analytics.....II-43
Table 8: German Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-43
1$150
   Table 9: German Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-441$150
   2c. ITALY.....II-45
A. Market Analysis.....II-45
Current & Future Analysis.....II-45
Historic Analysis.....II-45
B. Market Analytics.....II-45
Table 10: Italian Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-45
1$150
   Table 11: Italian Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-461$150
   2d. UNITED KINGDOM.....II-47
A. Market Analysis.....II-47
Current & Future Analysis.....II-47
Historic Analysis.....II-47
Migraine – Prevalence.....II-47
Migraine Treatment.....II-47
Abortive Drugs.....II-47
1$75
   List of Abortive Anti-Migraine Drugs Available in the UK.....II-48
Prophylactic Drugs.....II-48
1$75
   List of Prophylactic Anti-Migraine Drugs Available in the UK.....II-49
B. Market Analytics.....II-49
Table 12: UK Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-49
1$150
   Table 13: UK Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-501$150
   2e. SPAIN.....II-51
A. Market Analysis.....II-51
Current & Future Analysis.....II-51
Historic Analysis.....II-51
B. Market Analytics.....II-51
Table 14: Spanish Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-51
1$150
   Table 15: Spanish Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-521$150
   2f. REST OF EUROPE.....II-53
A. Market Analysis.....II-53
Current & Future Analysis.....II-53
Historic Analysis.....II-53
Ireland.....II-53
1$75
   B. Market Analytics.....II-54
Table 16: Rest of Europe Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-54

Table 17: Rest of Europe Historic Analysis for Anti- Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-54
1$150
III. COMPETITIVE LANDSCAPE 548$995
  
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 57)

Region/Country                 Players


The United States                 24   
Canada                             2
Japan                              5
Europe                            16 
     Germany                       2
     The United Kingdom            5
     Italy                         2
     Spain                         1
     Rest of Europe                6
Asia-Pacific (Excluding Japan)     9
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign